Q1 2022 International Flavors & Fragrances Inc Earnings Call

May 10, 2022

[music].

At this time I would like to welcome everyone to the Iff's first quarter 2022 earnings conference call. All participants will be in a listen only mode until the formal question and answer portion of the call to ask a question at that time. Please press star one on your telephone keypad.

If you would like to remove your name from the queue. Please press the pound key.

Participants will be announced by their name and company.

To give all participants an opportunity to ask their questions. We request a limit of one question per person.

I'd now like to introduce Michael Deveau head of Investor Relations you may begin.

Thank you good morning, good afternoon, and good evening, everyone. Welcome to Iff's first quarter 2022 conference call yesterday evening, we distributed a press release announcing our financial results a.

A copy of the release can be found on our IR website at IR Dot dot.

Dot com.

Please note that this call is being recorded live and will be available for replay.

Please take a moment to review our forward looking statements.

During the call we were making forward looking statements about the company's performance, particularly with regard to our outlook for the second quarter and full year 2022.

These statements are based on how we see things today and contain elements of uncertainty.

For additional information concerning the factors that could cause actual results to differ materially from forward looking statements. Please refer to our cautionary statement and risk factors contained in our 10-K filed on February 28, 2022, and in our press release, all of which are on our website.

Today's presentation will include non-GAAP financial measures, which exclude those items that we believe affect comparability.

A reconciliation of these non-GAAP financial measures to their respective GAAP measures is set forth in our press release that we issued yesterday.

Please note that we'll be using comparable results for the first quarter defined as three months of legacy ICF results January through March and three months of legacy <unk> results in both the 2021 and 2022 periods.

These results also exclude the impact of divestitures and acquisitions.

With me on the call today is our CEO Frank Claiborne.

And our executive Vice President and CFO Glen Rector, we will begin with prepared remarks, and then take any questions that you may have.

With that I would now like to introduce Greg.

Thank you Mike.

Hello, everyone. Thank you for joining us today.

I'm pleased to be speaking with you all and excited to share our perspectives for my first 90 days as CEO of Viasat.

During today's call I will discuss my initial thoughts since joining me.

And highlight our key operating priorities and commitments as a company for the full year 2022.

As I have spent the last 90 days meeting with ISS colleagues and key customers around the world.

Asking questions and listening in evaluating our business it has become even more clear to me.

<unk> has built a very strong foundation with incredible opportunities ahead.

Our business is both a robust diversified portfolio and driven team needed to continue leading our industry, while delivering sustainable profitable growth.

Simply put I am thrilled to lead and work alone so passionate team of more than 24000 employees.

With a shared commitment to strengthening customer partnerships and driving differentiated innovations.

Together, we are focused every day on the operational rigor and execution excellence.

Wired to deliver even greater value for customers and shareholders.

Before moving forward at first most acknowledged the human to human.

Humanitarian tragedy basing the Ukrainian people since washes invasion began.

As we have previously stated.

Unequivocally stands with the people of Ukraine.

Top priority remains the safety of our team members and their families in Ukraine and like many other global companies. We are working closely with local governments to offer assistance where possible.

Aligned with our core values several weeks ago, we limited production and supply of ingredients into Russia to only those that meet the essential needs of people, including.

Hygiene and medicine.

Our plan at this time is to continue to supply to the best of our ability in accordance with sanctions logistics availability and other key factors.

Now I would like to begin by sharing some initial learnings and insights from my first 90 days with ISS.

We'll then turn the call over to Glenn who will provide a detailed look at our first quarter 2022 financial results before providing commentary on our current outlook for the full year 2022.

After that we will open the call for Q&A.

Starting on slide six I'd like to reflect on what I've seen and heard from our global colleagues customers.

Bester suppliers and members of our board.

As I noted in my introduction ISS is incredibly well positioned from a portfolio perspective, with an exceptional depth and breadth of product offerings.

<unk> R&D platform that uniquely positions <unk> to win with our customers.

Our business is poised to benefit from sustained long term tailwind for profitable growth as we have demonstrated.

<unk> leadership in the most in demand consumer categories.

We're the largest player in our industry with unmatched global scale, a strong innovation pipeline and a highly diverse and balanced business mix across categories.

And any customers to create significant value.

Collectively these are attractive characteristics and a strong foundation to build upon moving forward.

Equally important however, other clear opportunities to improve our operating practices and ensure that we are achieving on our financial commitments. This is one of my top priorities going forward as I believe that consistent and consecutive delivery.

Of course within our control is critical to build trust and credibility.

CEO spin.

Specifically, we are working to cultivate a culture across our entire platform and motivate our teams and ensures accountability across the business.

We are continuing to enhance our operational execution with a renewed focus on instilling greater rigor and excellence aligning our compensation metrics.

Two kpis that are measurable and strongly correlated to value creation.

Please know that we're committed to investing in capacity digital R&D and commercial to capture incremental growth and productivity opportunities to ensure we deliver long term sustainable profitable growth.

With all of our initiatives. We are closely focused on consistently delivering on our short and long term financial commitments and creating enhanced value for all stakeholders.

Moving to slide seven I'd like to provide a bit more detail on the process underpinning our efforts to accelerate value creation across ISS.

Our success starts with enhancing our corporate culture to ensure that <unk> efforts worldwide are in line with our vision of strategic excellence.

It starts with establishing a renewed focus on winning and outlines the benefits for our team around the world.

To guide our efforts, we are developing a deeper understanding of the sources and drivers of value across the business to help prioritize our investment of energy and resources moving forward.

By understanding the facts, our extended leadership team will have the ability to make better business decisions.

<unk> investment allocations, which we expect will lead to greater financial returns.

With that understanding we will have better visibility into our strategic roadmap essentially setting our profitable growth agenda.

With the near and long term as we dedicate strategic investments on the highest value opportunities.

Underpinning everything we do will be a commitment to operational rigor and a culture of execution excellence across our platform.

Our results in the first quarter are beginning to reflect this commitment to operating discipline, which will remain a top priority for our leadership team going forward.

We plan on going into more depth on our strategy and financial outlook moving forward at an investor event that we were planning on having in the second half of 2022.

More details to come on that in due course.

Turning now to slide eight I would like to start with the foundational look at our portfolio.

Since my joining ISS in early February .

<unk> management team have begun a full diagnostic of our strategies and business model to ensure we were operating to the best of our ability.

As part of this process, we are thoroughly examined our business relative to the drivers of our current and future levels of profitability.

To ensure we capture the full cost of doing business, we have gone beyond traditional operating costs to account for invested capital such as Capex inventory and fixed assets.

Through this return on invested capital lens, we have incorporated all cost to create a more robust back base across our entire business portfolio to make better resource decisions.

Based on the preliminary assessment, here's a snapshot of our sub businesses.

As you can see we have a significant amount of high returning businesses, but also like most businesses, we identified opportunities where we can improve our performance.

And high performing areas of the portfolio, we will reinvest with conviction so huge strong profitable growth.

We will also explore all avenues to more efficiently manage resources and our medium return business with a goal of maximizing our performance.

And in areas of our portfolio, where returns are not meeting our expectations or below best in class benchmarks, we intend to optimize our capital decisions to improve returns.

Valuate appropriate opportunities to prioritize or exit the business.

As we move forward, we are fully committed to maximizing our portfolio to deliver the most attractive returns and value creation opportunities.

In fact for 2022, we have adjusted our long term incentive plan, replacing our net debt ratio with return on invested capital is a performance metrics to increase focus on capital efficiency.

Now before I dive into our first quarter results I want to reemphasize that I am committed to the four key operating priorities, we outlined earlier this year.

Building upon the strong sales momentum we established in 2021, we are first aiming to maintain volume growth consistent with overall industry growth rates.

To achieve this we are making significant investments to increase capacity.

Moving supply chain bottlenecks and driving greater revenue synergy opportunities.

On revenue synergies specifically it is all about expanded revenue growth opportunities and we feel good about the longer term prospects and the power of the portfolio.

To highlight an example, we recently were awarded access in Vanilla, a large opportunity with a global customer.

By leveraging heritage and <unk> global technical Knowhow in ice cream and heritage.

Yes, the Nellix sustainability program.

Asset offered a combination of technical expertise and sustainability that competitors do not have.

The result was not only strong potential revenue in flavors, but also incremental value creation for total asset, including protein multipliers and LPG.

I am pleased to see in my early days the traction we are making and excited to dig in with the business to unlock more growth opportunities ahead.

Turning to slide 10, I'd like to provide an overview of our solid performance for the first quarter.

Despite the macroeconomic challenges of today's environment, we achieved good sales profit.

And growth across our business.

In the first quarter Iff's delivered $3 $2 billion in sales, representing 31% growth or 13% growth on a comparable currency neutral basis.

While inflation and global supply chain logistics restrictions continue to impact our profitability margin, we achieved 9% growth in our comparable currency neutral EBITDA.

We also achieved strong adjusted earnings per share excluding amortization of $1 69 for the first quarter.

And as I mentioned, we are evaluating and implementing specific initiatives to ensure we continue to navigate the future headwinds during the remainder of 2022 and beyond.

As a result of increased working capital requirements higher Capex and seasonality our free cash flow results were negatively impacted in the first quarter.

Looking ahead I can assure you this will be a significant focus area for the remainder of the year and we expect strong improvements in the back half of the year.

In terms of deleveraging the balance sheet, we remain on plan as our net debt to credit adjusted EBITDA ratio was four two times.

We also delivered meaningful synergies and productivity gains were more than $30 million in the quarter, including operational efficiencies and deal related synergies.

As mentioned, we continue to prioritize portfolio optimization and are making strong progress on the divestiture of the microbial control business.

It should be noted that the anticipated closing of our microbial control business is now expected to happen on July one versus June one.

Previously to provide more time to complete the separation work streams and minimize disruptions and risks to the microbial control business upon close.

With that I'd like to turn the call over to Glenn to provide a closer look into our first quarter financials.

Thank you Frank good morning, and good afternoon to everyone. Let's start on slide 11 with sales performance of each of ipads for businesses.

Together, Mirisch health and Biosciences.

And pharma solutions achieved $3 $2 billion in sales revenue in Q1 reps.

Representing comparable currency neutral sales growth of 13%.

No all our sub businesses posted year over year comparable currency neutral growth in the first quarter.

<unk> delivered the most substantial growth with significant broad based strength in our flavors ingredients and food design businesses.

Health <unk> Biosciences, Similarly achieved strong sales growth, having managed headwinds and the health business.

The scent division carry strong momentum from last year to the first quarter with strong results in fine fragrance consumer fragrance and ingredients.

Lastly, pharma solutions also achieved currency neutral sales growth driven by the division's continued strength in its industrial business and resumed demand for pharma.

In terms of sales growth contribution pricing increased approximately 8% and volume grew approximately 5%.

Turning to slide 12, let's walk through our profitability in the quarter.

First quarter, adjusted operating EBITDA totaled $702 million.

Representing 9% comparable currency neutral adjusted operating EBITDA growth versus the first quarter of 2021.

Our adjusted EBITDA margin in the first quarter was 21, 8%.

And on an inflation adjusted basis would have been approximately 175 basis points higher or approximately 23, 5%.

Margin did come in better than we expected in the first quarter due to stronger than anticipated volume growth better cost management as well as the fact that a significant amount of our higher inflationary costs remains in inventory.

Did that impact the P&L to the degree originally anticipate.

However, this was largely timing related and will change as we progress throughout the year.

Our results is a charge of approximately $20 million related to expected credit loss on receivables from customers located in Russia and Ukraine.

While the macroeconomic environment remains incredibly dynamic with continuing inflationary pressures at the moment. We are pleased with the actions taken by our teams to manage through these challenges we.

We took a very proactive approach we quickly instituted broad based pricing actions across our portfolio in response to these pressures.

Sequentially. The actions we have taken have resulted in a full dollar cost recovery of total replacement cost in the first quarter.

Unfortunately since our February earnings call, we have seen additional increases in raw material logistics and energy costs and are diligently working with our customers on incremental pricing actions.

One important note to call out is that we are seeing the strong cost increases flowing to inventory, which are due to our inventory days.

The higher cost will eventually impact the P&L as we progress through the balance of the year.

Now on slide 13, I would like to highlight the underlying dynamics and first quarter performance of each of our business segments.

In the first quarter nurses strong comparable currency neutral sales growth of 16% was led by double digit growth in fluid design and ingredients.

This segment's comparable currency neutral adjusted operating EBITDA growth was also strong at 14%, primarily driven by the divisions pricing actions volume growth and productivity gains.

In health <unk> Biosciences double digit growth in health microbial control and grain processing and high single digit growth in animal nutrition, and cultures and food enzymes drove comparable currency neutral sales growth of 10% for the first quarter.

Similar to nourish the segments comparable currency neutral adjusted operating EBITDA growth of 8% was led by pricing volume growth and productivity that help offset mix challenges.

Fine fragrance continued its strong rebound with double digit growth in cosmetic active and fragrance ingredients continues to perform above expectations.

As for consumer fragrance business experienced modest growth in the first quarter.

Overall percent.

6% comparable currency neutral sales growth comparable currency neutral adjusted operating EBITDA declined 2% as inflationary pressures outpaced pricing for the quarter.

As a reminder, there is a delay in pricing recovered about 18 months before you fully recover inflation via price increases.

Finally in pharma solutions, we saw double digit growth in both pharma and industrial to deliver 10% comparable currency neutral sales growth for the quarter.

Volume growth and productivity gains helped drive 10% comparable currency neutral adjusted operating EBITDA.

Now on slide 14, I would like to address our cash flow and leverage positions.

In the first quarter increased working capital requirements.

Part D seasonality and in part due to increased values of inventory and accounts receivable driven by inflation as well as higher capital expenditures negatively impacted our cash flow results for the quarter.

In the first quarter Capex totaled $132 million, representing approximately four 1% sales.

As a reminder, we anticipate R 22, capex to be approximately 5% of sales due to 'twenty, one capex carryover and increased investments in capacity expansion in key technologies, which will help support growth while also lowering logistics costs.

From a leverage perspective, we are on plan and are continuing to make progress toward achieving our deleveraging target.

Q1, and the net debt to credit adjusted EBITDA ratio was four two times.

Gross debt for the quarter totaled $11 7 billion and we finished the first quarter with cash and cash equivalents of $662 million.

Despite the global financial pressures, we remain on track to achieve our deleveraging target of three times or lower by year, three post close which will be supported by our food preparation divestiture sale of our microbial control business and other non core business divestitures.

Slide 15 provides our revised business outlook for 2022.

We are adjusting our expected full year 'twenty two revenue up to 12, 6% to 13 billion.

<unk> 12, three to $12 7 billion.

This reflects the effects of additional anticipated pricing actions not incorporated in our original guidance, primarily due to the additional inflationary pressures.

This revision also reflects the expected completion of our microbial controls divestiture on July one one month later than originally planned and the acquisition of health right products completed in April .

In addition, our outlook takes into account a weaker euro to dollar currency outlook for the balance of the year.

We continue to expect adjusted operating EBITDA in the range of two 5% to $2 6 billion as we continue to target full cost recovery of additional inflationary pressures.

The price increases.

On a comparable currency neutral basis. This translates into sales growth of approximately 9% to 12% versus 6% to 9% previously for the full year and comparable currency neutral adjusted operating EBITDA growth of approximately 4% to 8% which is <unk>.

Unchanged.

It should be noted that while we have increased our sales expectations for the full year due to incremental pricing, we have reduced our volume expectations, given a more challenging environment, including loss revenues as a result of the Russia Ukraine War.

<unk> global supply chain issues.

And anticipated softer consumer demand as a result of higher energy prices and general inflation negatively impacting consumer spending.

One data point is that in early Q2, we have already seen volumes softened and for the full year. We are now targeting low single digit volume growth and high single digit pricing contributions.

Also based on cart market foreign exchange rates, we expect that foreign exchange will negatively impact sales in 2022 by approximately four percentage points versus two percentage points previously and adjusted.

<unk> operating EBITDA growth by approximately five percentage points versus 4% previously.

These changes now reflect current market exchange rates, particularly the euro where we are assuming that remains at 106 to the dollar for the balance of the year or a blended full year rate of approximately 108 to the dollar.

We are also confirming our 'twenty two capex spend will be approximately 5% of sales.

In terms of the second quarter, we continue to believe that sales growth will be driven by price increases with volumes contributing much less they did in the first quarter.

From an adjusted EBITDA perspective, we expect to be in the range of $640 to 650 million pressured by unfavorable impacts of currency as well as higher inflationary costs flowing from inventories to the income statement.

As I wrap up I want to revisit the four key areas of focus we touched upon in February to update you on our progress as.

As a reminder, our four key priorities for 2022 are maintaining strong sales momentum executing broad based pricing actions, capturing synergies and productivity and accelerating our non core business divestitures.

Overall, we feel good about our progress across all four areas in Q1 and are confident in our ability to deliver on these commitments this year.

In terms of supporting strong sales momentum, we are increasing our capacity across constraint portions of our portfolio enhancing our supply chain efficiencies.

Most notably in our ATB pharma solutions and ingredients business to ensure that we maintain our volume growth in line with or above the industry.

Relative to executing broad based pricing actions in an effort to react more quickly to the days of balding environment and better prepare for Tomorrow's challenges, we have significantly enhanced our processes implemented new pricing tools and established core pricing teams to oversee each of our busy.

These units are.

Our focus has been centered around minimizing the amount of time loss between inflation signals and customer pricing actions to ensure that we quickly adjust pricing to protect profitability.

These changes we successfully implemented our first round of pricing actions and recover the total cost of inflation in Q1 'twenty two.

Given additional known inflationary pressures and a lot of uncertainty regarding the future path of inflation. This remains our highest priority.

Accelerating our productivity and expense synergy efforts also remains a key priority and increasingly important in a more challenging macro economic environment.

To this end, we were able to deliver over $30 million of operation efficiencies and deal related synergies in the first quarter above our expectations.

As a result, we expect to exceed our original 100 million full year cost reduction target, which is net of reinvestments.

This higher level of productivity is helping office offset lower full year volume expectations.

As we look to accelerate our long term productivity opportunities, we have sharpened our focus on three large areas of productivity.

Procurement efficiencies, notably in indirect spend.

End to end operations efficiencies inclusive of digital enablement yielded mixed enhancements and logistics efficiencies.

And expanding the scale and efficiency of ISS global shared service platform.

Importantly, we will remain prudent in protecting key topline investments, including R&D customer sales and service and technology.

We plan on providing more details of these initiatives at our Q2 earnings call.

Finally, we made further headway in accelerating our non core divestitures. We are on track to successfully complete the sale of our microbial control business.

July one.

We are also targeting additional portfolio optimization and noncore businesses, the best figure opportunities to Delever our balance sheet.

Best Greater resources toward our higher return businesses we.

We are making very good progress in early noncore business in marketing efforts and have already received strong interest from perspective buyers.

Should these transactions go through we anticipate that they will in aggregate be accretive to our go forward growth rate and margin profile with that I'd like to pass the call back to Frank.

Thanks Glenn.

Turning now to slide 16.

As I look back on the last three months I am proud of the work underway to ensure that ISS next chapter is exploit this yet or.

Solid results, including consistent volume growth across our portfolio reflects iff's critical role in the consumer goods value chain, particularly amid such a challenging operating environment.

While market volatility will inevitably continue to impact our industry, we will closely monitor developments strengthen our financial discipline and fortify our portfolio to address ongoing pressures.

With the strong foundation, we established in the first quarter I remain confident in our ability to achieve our full year 2022 financial targets improve value creation and further cement our key operating priorities.

Having begun the process of our strategic refresh I look forward to sharing additional updates on ISS long term strategic vision at an investor day in the second half of 2022.

I know many of you have questions as it relates to my perspective on Iff's long term financial targets.

Given we're going through a robust review of our value creation opportunity via our strategy refresh I ask that you give us time to appropriately assess our long term financial objectives.

Want to thank you very much for all of your support.

I know that the best is yet to come for ISS with that I would like to now open the call for questions.

Thank you and at this time, if you would like to ask a question. Please press star one.

One on your Touchtone phone, we do ask that to give opportunity to all participants to ask a question for you request you limit yourself one question per person and we will take our first question from Gunther Zachman with Bernstein. Please go ahead. Your line is open.

Hi, Good morning, Thanks for taking my question Gunther <unk> from Bernstein.

The three percentage point increase in organic sales right Frank to 9% to 12% that's almost unprecedented pretty price may given your tenure at the company and what businesses do you expect to see the biggest price increases and what is necessary to include demand reduction.

Part of your guidance and then I've got a question one b as well, but I will post that.

Sure John So I'll, let Glenn maybe give some specific color on the different business segments, Yes, Hey, Catherine Let me, let me first sort of answer by the way. Good afternoon, CEO will unpack the $300 million, so sort of the nature of that and I will talk about sort of where it sits so the $300 million change as a function of several.

Items first of all we had some portfolio adjustments to the acquisition of health right and then one additional month of Mcrobie controls.

That's about $130 million of incremental revenue, that's completely offset with our foreign exchange update I E. The stronger euro.

Stronger dollar relative to euro rather basically offsets that completely from a revenue standpoint.

The residual is we have incremental pricing of around $370 million and thats all related to raw material increases, which I'll come back to and as we mentioned on the call are actually bringing down volume balance of the year.

For a full year down about $100 million from our original plans. So a little over a half a point full year, we actually were better in the first quarter by a point. So we're taking that in the balance of the year down by $100 million.

Where we're seeing basically the impact of the price slashed volume pretty much mirrors, where the cost increases are occurring so we've had more material cost inflation in our nourish business and other businesses. So that was thats why we see the the higher growth rates in that business, but we are continuing to see the impact on all the businesses.

So nobody is sort of is exempt from the second round of this $300 million in terms of kind of overall pressure a bit more in Europe than the other business because of the raw material impact.

Great and thanks, Glenn and then at <unk> can you provide an update of where you see cost inflation for this.

And as far as you can for next year I know you don't guide for 2023, yet, but if you can share how much earnings you expect.

To recover next year from costs that you incurred loss for this year. Please.

Yes.

Is a great question Gunther and also something that we're working on now where we don't really have a status in part because there is two parts of the equation.

One is to understand the overlap of the latest round of raw materials into next year. So there is a carryforward, but then equally are basically the pricing dynamic. So as mentioned we are having to go back in the market because of incremental pricing. So there'll be a full year effect of that as well I would also remind the group that last year, we were still in the hole.

I E. The inflation exceeded pricing in 2021 by $200 million.

So we're still plan to basically go after a full capture unfortunately with the latest edition of inflation, it's just going to take a little bit longer into 'twenty, three to sort of get us back to whole.

And we will take our next question from Ken <unk> with Baird. Please go ahead. Your line is open.

Thank you good morning, everybody and Frank welcome to the industry Congrats on the new role.

I guess my question was more so on slide six we have the opportunity section in the <unk>.

Third one in terms of reinvesting in capacity.

R&D and so on can you just expand on that and if you could just sort of assess the technological capabilities within the company. The way you see it at this point I know it's very early.

Your 10 year life. Thank you.

Yes, Janssen Hi, it's Frank and thanks for the welcome and also for the question a couple of things I want to highlight.

Is and you look at that slide I do want to start with the fact that.

I am very still encouraged by the opportunity that we have in the industry trends look very strong overall in the long term around sustainability health and wellness and naturals.

Also <unk> with its highly diversified business mix across categories regions and customers I think positions us very well.

When you look at that slide when we talk about the opportunities I think a couple of things I would highlight there is one is we are focused on really doing everything around our culture of execution excellence, that's going to be really important for us.

Through our talent instilling accountability and also our strong linked to incentives for our teams as far as reinvesting clearly we are going to look at that that's going to be a part of our strategy refresh process and we'll be spending a lot of time on that in the second half of the year when we share our.

Our overall plans, but.

Early view would be clearly we need to continue to build our capabilities around digital data analytics, we're going to be really important and then also will invest in our commercial efforts as we see opportunities for continued profitable growth and then we're also doing a deep dive in our R&D portfolio and we will look at the best.

Innovation in R&D opportunities to invest behind as well, but much more to come as we head to the second half of the year.

Okay forward to the Investor day. Thank you.

And we will take our next question from Jonathan Feeney with consumer edge. Please go ahead. Your line is open.

Good morning, Brian Let me add.

Add my congratulations you've been very vocal about taking pricing across a broad range of customers.

These are.

It's not quite like gas prices right. These are very sensitive.

Industrial relationships, where the companies are intertwined and you.

You mentioned in the script, how it takes time, but I wanted to ask specifically one of your customers do pushback on pricing what do they say what are the common pushback together, if somebody says no to price and what's the reason when that happened.

Eric.

Is that happening or are those kinds of things getting said now more often than January as some companies maybe some of your customers are under a little bit more stress now than they were in January .

Yes, John Thanks for the question I'll start over.

Glenn add.

Add on as well.

One I think the teams have done a really good job starting off this year and working with customers to try to recoup.

The significant inflationary pressures, we're seeing in the business. So we have I think a strong value proposition. We have strong commercial teams that are working very closely with their customers to really understand the importance of us recouping.

Our.

And placed and what we're seeing from an inflationary perspective, so I do feel we're off to a very good start there are pushed back. So I think some of the push backs are in some of the smaller customers some of our emerging market customers where price is much more sensitive we are seeing pushback there, but all in all we feel as though.

We are in a good place and we will continue to work closely with our customers to navigate which as we all know unprecedented times when anything Brad Hey, Thanks, Jonathan for the question I would say first of all obviously, we're not unique as every industry is experiencing substantial increases in inflation and all.

Our competitors are out there basically taking prices up as well and as you're well aware as it relates to our value add from our customer supply chain or attended we tend to be a relatively sort of low cost high value add relative to their overall value change and I would say simply put with six.

2% of our cost structure related to raw materials energy and logistics, it's sort of impossible for us to absorb those levels of increases and rather as our customers will appreciate we're in business to really provide them superior solutions, which requires significant investment in innovation customer service capabilities.

Building and maintaining a very robust global supply chain I would remind everybody, we're adding $200 million of Capex. This year alone we had to build out so that.

The value, we add to our customer and as a result of that we can't sort of if you will speculate on material costs and our customers appreciate that frankly, where we sit relative to our value add they completely appreciate.

What we're doing for them and Thats been reflected in the success of pricing I will note, though there are some sectors as we mentioned in <unk> as an example that theres a lag. So it's not every single customer no doubt a frontier in terms of in terms of the pricing, but in general the.

Level of productive dialogue has been very very good with our customers.

Thank you.

And we will take our next question from Mark Astrachan with Stifel. Please go ahead.

Yes. Thanks.

Everyone I guess, maybe to start Glenn what are you assuming for volumes throughout the rest of the year.

Our guidance would suggest flattish I guess <unk> you alluded to APRA.

April trends softening were were they positive.

Curious to if you've seen competitors pricing.

And the words has shifted more iff's impact and then <unk>.

Thank you I appreciate the commentary on still evaluating the business I guess the question.

Most often is the 26% EBITDA margin target most seem to think that Thats just just.

Unrealistic at this point, maybe if you could talk a bit about that that would be helpful. Thank you.

Thanks, Mike So I'll start off with our volume outlook, 5%, where the actuals for the first quarter, we're actually projecting 1% for the balance of the year. So relatively flattish I would remind everybody. We have a very strong overlap in the last three quarters for the last three quarters of last year.

On average around 10%.

Terms of currency neutral sales of which that was around 8% volume each of the quarters, a very stronger and thats why we actually planned the second half of the year more flattish versus the first half of the year.

Why we've taken it down is basically taken the balance of the year down about $100 million in revenue that is basically split into two components. One is the direct impact on Russia, and Ukraine volumes in the second half is really a combination of supply chain and demand issues is it supply chain would include a combination of raw material.

Access as well as China, and then generally we just we just feel that we're seeing early signs relative to the consumer pulling back we really don't view this as a not being competitive on a pricing standpoint, but frankly, it's just what we're seeing in the consumer can it's manifested itself later in the last couple of weeks a little bit more in the.

The home and personal care side of the business versus sort of food and beverage or pharma side. So we're not sure honestly, whether thats sort of an end consumer.

Minera pullback or adjustment of inventories, but we're just frankly, just being cautious relative to sort of what's going on in the global economy.

Hey, Mark it's Ryan Thanks for the question.

As I mentioned in some of the early remarks, we are working through our strategy refresh process and that does include our long term plan in detail and looking at our current inputs into.

Through our plan.

We will need some additional time to appropriately assess our long term financial targets.

My immediate focus our management team's focus is on delivering our 'twenty two objectives.

The financial goals that we're outlining here this morning, which of course, there's a lot of focus on pricing as you continue to hear productivity and important levers in working with our customers to grow our absolute sales and profit as we manage through the significant inflationary period.

Longer term.

Mark There is no doubt in my mind, we have a lot of value creation ahead of us in the company.

I believe our business will generate sustainable profitable growth and it will yield margin expansion over time.

As far as your specific question on the 26% adjusted EBITDA target I think it's really safe to say as we look at where we are today.

And you look at how the World has changed we're not going to be able to achieve that 26% adjusted EBITDA target in 2023.

With that said as I mentioned I do want the time to come back and share with you in the back half of the year, our plans and also our focus on driving really strong profitable growth for the future.

We'll take our next question from Heidi <unk> with BNP Paribas. Please go ahead.

Good morning, just to clarify on pricing again, so youre looking to fully offset the dollar headwind from inflation for the full year. I think you said can you once again explain how you hope to achieve is because its normal industry practice for certain parts of your portfolio makes sense to have a lag.

Is there another segment offsetting that lag for the full year. Thank you.

Yes, where we actually are lagging Heidi as a reminder, we're 200 million behind last year. So there were sort of catching up from last year and capturing.

A large the largest percent of this year, but there is still a lag that will be going into 'twenty three as well.

Okay.

But on a full year 22 basis I think you had said you're looking to fully offsets right. So you won't have that squeeze from raw materials.

Yes.

Be clear, we have $200 million from last year from 'twenty, one that we didn't capture we began to implement so if you look at the cumulative 21, which is really the second half of 'twenty, one and all of this year, we're still $200 million odd.

Okay and then the idea is to pass that on as we go into next year. Okay. Thank you.

Thank you and I can say.

We will go next to John Roberts with Credit Suisse. Please go ahead. Your line is open.

Welcome Frank just one question.

One of the largest R&D budgets in the industry and the major drug firms are going to be best in class R&D management here.

But we don't get an innovation or a vitality index.

At any stage gate processing reported hard to know how productive R&D as to what the right level of spend is.

<unk> had a chance to kind of go through the processes within RMB in the center of excellence model and so forth.

There are changes that need to be made there.

Yes, Thanks, John for the question.

Just.

Some of them are put in a couple of quick points and based on my experience one I have been very encouraged by.

Some of the recent business update into our R&D centers I, just got back from Palo Alto in California and.

Really good innovation, taking place some of the work, we're doing and with regards to our enzymes with regards to some of our Sam and sustainable delivery systems flavor technology. So I'm encouraged early on what I'm seeing.

I think what I would highlight is from an R&D perspective, theres three things that come to mind. One is making sure you have the best talent and Thats, a major focus for us and allowing our scientists to innovate number two is we have <unk>.

Processing model, where you have very close connection with your commercial teams. So your arm in arm. Your scientists in your commercial teams really working on innovations that are going to be meaningful from a customer and consumer perspective, and thats a major focus that we're putting in place and the number three is doing it in an efficient way in <unk>.

Putting our capital against the biggest R&D opportunities. So early on encouraged this is going to be a focus for us and this also will be a part of our second half Investor day, we will come back and share.

More about some of the exciting projects, we're working on in our pipeline.

Okay.

And we'll take our next question from Matthew Deyoe with Bank of America. Please go ahead. Your line is open.

Good morning, everyone.

Frank.

And as we often hear about <unk> assets and senior management.

<unk> has been pretty elevated following the <unk> acquisition and that perhaps the broader leadership team is relatively experienced.

How do you how do you plan to address this as the new CEO and you think about the team that's around here.

So Matt that's an important question and what I would say is that.

We have to do everything we can as a management team to really build.

As I've been saying the right culture.

The right focus for the organization.

As I highlighted in my prepared remarks, we have a tremendous opportunity in front of us with ISS.

But we do need to deliver.

To deliver and we do need to focus on execution excellence.

Yes, there has been some change in the management ranks.

That is something that obviously we.

All take seriously, but our focus right now is with the team that we have in place is really to be laser focused on delivering and working on behalf of our customers to create value in the marketplace. So.

That's really the focus and I am excited about the passion and the energy received from so many iaff offers around the world have had a chance to engage with a lot of them.

We're really in a good place as long as we can focus on the four priorities that Glenn mentioned earlier I.

I do feel good about our opportunity as we work through 'twenty, two and then as we start to build the company for the future.

And we will take our next question from Mike Sison with Wells Fargo. Please go ahead.

Hey, good morning, welcome Frank.

I guess your background has a lot of integration.

Sure.

And so.

I'm kind of thinking when you think about the Dupont acquisition.

MB and putting the company together.

It does seem like the initial outlook for 2003 or the sort of initial goals are going to a little bit off so.

When you think about.

How we should measure assist there will be inevitably a successful deal together what do you think we need to look forward I know there are a lot of this will probably come in in your analyst day or second half.

Im certainly looking at Cleveland as a possible site I'm joking, but thanks, Mike.

Uh huh.

What should we think about as as the metric or couple of metrics that well.

At the end of the day Wood wood.

That.

Let's suggest this has been a really good deal over time.

Yes, Mike I think recognizes.

We recognize as where we started we also are in some unprecedented times from an inflationary perspective.

Also what's happening.

With regards to China, and Covid Lockdowns in what's happening with the award and the impossible recessionary pressure. So clearly the world is changing significantly.

I would say.

Is that we will spend time like you said in the second part of this year, but really look at it.

Our focus and I keep using this phrase about driving sustainable profitable growth.

We want to have a.

A company, that's growing top tier within our peer set and from a topline perspective.

Good strong leverage throughout the company.

Our relentless focus on constantly improving our productivity and making sure. We're doing everything we can to deliver for our customers and our shareholders. So I think that will be some of the metrics and we will come back obviously as we get into the second half and give you specific metrics, but thats how I would.

Do you think about it Glenn I don't know if you want to Hey, Mike I would just add one by the way I lived in Cleveland I'm not sure I'm allowed to come back, though but really at the end of the day, we are trying to deliver a superior outcome for our shareholders and the way to do that as Frank had mentioned is to make sure. We outpace the top line versus the industry. So having superior top line growth and secondarily a suite.

<unk> return on invested capital the way we are doing that is actually driving significant productivity, which we believe there is and allowing that to basically reinvest back into to help accelerate the top line and to continue to actually drive some of that to the bottom line, while we're optimizing our portfolio. So to Frank's point that will be sort of a major agenda when we get to.

Later in the year, mainly in Cleveland.

Mike just one last one and I did mentioned that ROIC is now part of our metrics as a team. So that's something that we've incorporated.

Okay.

And we will take our next question from Lisa <unk> with Morgan Stanley . Please go ahead.

Hi, good afternoon, and thank you for taking my questions I have two.

First one is can you talk a little bit on how the growth has been evolving in the first quarter through the different regions and how you expect volume growth to develop over the coming quarters or through the year.

So the plus and minuses would be very helpful. And secondly, can you share a little bit what youre seeing in your innovation pipeline.

And what segments are you seeing stronger levels of innovation and also do you see sort of any levels of reformulation activity. Thank you.

Good morning, Lisa so relative to the first quarter and balance of the year relative to regions. Our strongest areas have been the developed markets. So a combination of Europe and North America Laggards has really been actually greater Asia is slow or slower growth in the first quarter. We expect as we look at the balance.

Of the year continue to have a little bit of challenges in greater Asia, particularly China as we mentioned likely also to see a slowdown meaningful slowdown in Europe , given the what's happening from an economy standpoint, but are still sort of fairly optimistic on combination of North America, and Latam as well.

Yeah, and just real quickly we're doing a lot of R&D work and health <unk> Biosciences area with regards to our enzymes and focusing on probiotics and also laundry dish programs with global key accounts, we have work in some of our plant based protein and dairy alter.

It is a couple of other quick ones to highlight.

In the <unk> area some of the renewable biodegradable fruit in fragrance ingredients. We're also really.

Focusing and nourish around a lot of our flavor technologies and I highlighted one of the big wins that we had with vanilla recently with one of our customers. So we'll spend a lot more time here on the pipeline and the portfolio as I mentioned coming up in the second half of the year.

And we will take our next question from David Begleiter with Deutsche Bank. Please go ahead. Your line is open.

Thank you and good morning, and Frank Congratulations as well on the new role.

Frank filling up your overview of the company do you think iaff does a good job capturing the full value.

Products with the customers.

Secondarily, what do you think of IPF does better than competitors and everything is lacking versus competitors. Thank.

Thank you.

Yes, very good questions I think when you say what do we do better than I'll start there I do think our global scale diversity of ore and breadth of our portfolio and how we engage with our customers.

I think we are leading in many categories in many many areas and thats something that we will continue to leverage and it also allows for us to work quickly with customers to co create solutions with them. So that to me is a big strength of ours.

What are some of the competitors due to our competitors that are focused in certain areas that.

I do think have done a nice job from a pricing perspective or have in certain categories, a little bit better margin construct and we do and that's really why we're staring into our portfolio to make sure that we put our resources against the best opportunities and where we see those opportune.

We're going to invest and then where we see opportunities to improve we'll focus there and then in some areas, we will pull back investment or possibly even divest if we need to solve is going to be some things that we're going to be looking at to make sure that we continue to build the strength around our portfolio, but those were some initial thoughts on how I think.

Are lining up with our customers and then how we compare to some of our competitors.

Okay.

And we will take our next question from Lauren Lieberman with Barclays. Please go ahead. Your line is open.

Great. Thanks, good morning.

I was curious I know you touched earlier on.

Tightening and how quickly you move during the first quarter and Glenn in your comments, you more or less referred to that.

<unk> press release that.

That's put out discussing kind of new approach to pricing.

I mean.

It feels like that's the first moment.

Company now with a much greater scale really taking on the role of industry leader and I'm just curious what if anything you've seen in the competitive landscape. How others are now approaching pricing at the industry as a whole is moving faster.

I know, it's been a short period of time, but it's an interesting question in the 10-K ISS roll again as industry leader.

This newfound scale. Thanks.

Yes. Thanks for the question, we actually as you recall in the.

The fourth quarter.

Signaled pretty quickly given we saw this large tsunami of inflation and went out very quickly in the fourth quarter. The first round that press release was really in advance of the second round.

Our competitors are seeing exactly the same.

Inflationary pressures as well so I think that was intended really that help our our teams relative to the customer dialogue sort of understand the dynamics and the impact on the business. Hence the purpose of the press releases as I did mention Eric all of our competitors as Youre well aware are basically in the market.

The same thing.

Our passing along prices in time as well, we just we just move SaaS given we saw in the fourth quarter and as I mentioned on the call. We really also invested in I'll say in infrastructure around the organization to make sure. We're more closely monitoring what's happening in the market and just moving much much much quicker because I think we are concerned that this even the sector.

Round, maybe the second of others. So we just want to be prepared to do that that was the purpose of that that press release.

Sure.

And we will take our next question from Jeff Zekauskas with JP Morgan. Please go ahead. Your line is open.

Thanks very much.

Hi.

Originally when you bought <unk>.

Two pump business, the idea was to take out $300 million and costs and to spend about $335 million to do it.

And to date.

I think ISS has spent $32 million.

So it seems that the.

Original cost reduction program.

Is moving more slowly.

That is why arent the chargers larger.

And secondly.

On slide eight where you lay out your return on.

As to capital distributions.

It looks like about a third of the company has unsatisfactory returns.

What conclusion to draw from that does that mean that you really need to overhaul star.

Structure of the company dramatically or do you draw a different conclusion.

Yes, let me maybe I'll take the second one and come back to the first one is the euro.

Our conclusion is correct in terms of a third argue a third of our business from a capital utilization standpoint is to improve and there are two major levers so not surprisingly as it relates to some of our non core divestiture work. They would fall within that basket. If you will continue to optimize the portfolio as one lever the second is.

Really thinking about ultimately a combination of capital investment in those businesses and in addition, how we think about optimizing the profitability so as part of the.

Frank's comments about our refresh strategy, we are thinking about the portfolio in that way and by the way. That's also in the spirit of taking some of those dollars and moving them up to the far left of that chart and accelerating the growth dynamics of the higher return segments as well relative to our cost savings as a reminder, we get.

We are the farthest behind simply because of this environment is harder to materialize. The other half of the $1 50 were sort of midway through in terms of capture to your broader point about how we think about restructuring opportunities.

Move beyond a discussion of just synergies deal related synergies was too narrow and we really are focusing more broadly on productivity as I mentioned there are three large buckets operations procurement and then shared services.

The first two of those are likely to have relatively low onetime costs because they are really optimizing operations digital throughput some fixed cost reduction indirect material purchases the latter being shared service probably will have.

Some one time restructuring charges as we build out our current infrastructure and continue to add capabilities into that network.

And we'll take our next question from Josh Spector with UBS. Please go ahead.

Yeah, Hi, Thanks for taking my question I guess, just a couple of follow ups on the price raws dynamics. So just curious now whats your length of visibility on the raw material front. So how far ahead are you seeing today and as you look at your pricing guide for the year I guess of your pricing of your second round increases that to capture that.

The ability that you see now or are you pricing ahead of that.

Does your guide imply a low double digit price exit rate for the year at this point. Thanks.

Yes.

Generally we're looking out until the third or fourth quarter for the raw materials energy is more problematic as well as logistics that tends to sort of.

It's really kind of here and now if you will in terms of kind of what's happening in the marketplaces. We've done best estimates based on sort of where the markets are trading relative to energy as well as logistics costs, particularly the raw materials are sort of about six months out but some of them have been a lot of them and then locked in some of them have not so.

So we are continue by the way we're continuing to monitor every single week, we sort of have an update on how we're feeling about the market in general over the last sort of month six weeks, there's been some ebbing and flowing so slightly higher in energy. Some some relief in raw materials, but it hasnt materially different than that 350 ish.

Number that I provided earlier, so relative to sort of a carryover for next year, we still have to sort of work that through as I mentioned, it's a combination.

Whats the tail of this year's annualized raw materials, and then very importantly, we got to figure out as well as the tail of the pricing actions into next year as well.

And we'll take our next question from Christopher Parkinson with Mizuho. Please go ahead. Your line is open.

Alright. Thank you Greg is now that you've had just a couple of weeks to evaluate.

Portfolio can you just named kind of two to three sub businesses that Youre. Most excited about in your remarks, you mentioned probiotics and protein.

From your background whats getting you the most excited on a go forward basis. Thank you.

Sure I'll be quick because I know.

We've got a couple more waiting on as well, but just to give you. An example enzymes I think are.

Or is that I'm excited about.

And we're going to deploy resources to drive growth and really mixed improvement there over time.

There was also I think some really solid areas such as fabric care. We think there is opportunities to improve our cash flow there and then.

We will continue to look at some of the underperforming areas as well and I think this is.

Something in Glen highlight on our four priorities, which is why we have made the decision to.

Exit for instance, our microbial control business and we've announced that divestiture. So those are some examples and like I said, we'll spend much more time.

Opening up and sharing a lot more as we get to the back half of the year.

And we'll go next to Andrew touches with Barclays Credit. Please go ahead. Your line is open.

Yeah, Hi, good morning.

Perhaps a question for you.

If you take a step back and look at the balance sheet, we're a little more than a year into the NMB transaction and Leverages essentially where it was at closing.

And I think I heard you said youre dropping the balance sheet metric from executive compensation. So I guess I just wanted to understand.

Your confidence and the ability to hit that 3.0 times Mark the beginning of 2024, how critical are these divestitures that youre talking about Andrew.

And is it right to think that maybe the scope for divestitures can expand particularly as we lap that two year IRS anniversary for Adam.

Yes, so just a clarification reasonably dropped the balance sheet metric as we launch the new three year plan. So to some extent this is the window beyond sort of our deleverage so.

I am very very confident that we will hit three less.

We will be closing on the microbial controls business at the end of this quarter thats going to be net proceeds of $1 1 billion as I've mentioned in the past we have three to four additional deals that will cumulatively add one five to $1 7 billion of gross.

They are proceeding nicely by the way despite the sort of volatility in the market. They are attractive properties strategically that alone will basically get us to the goal independent of cash flow to the last point of your question. We're going to continue obviously to take a look at the portfolio. That's part of the strategy refresh.

Which will probably have for additional opportunities to continue to prune the portfolio, but nothing to announce at this point and nor do we need that to accomplish that goal. So thanks for the question.

And there are no further questions at this time I will turn the call back over to Frank Cleveland for any closing remarks.

So thank you.

To all for joining our call I really appreciate.

Your interests in.

The time, we spent this morning discussing our first quarter results.

Hopefully you can hear from myself Glen and on behalf of all of Iff's, We're really encouraged and excited about the future and we look forward to sharing more about our plans as we head to the second half of this year and also want to reiterate just how focused we are on.

Our company <unk>.

Sure were executing and working with our customers to deliver important solutions for consumers around the world. So thank you and we look forward to.

Speaking to you soon.

Okay.

Thank you and this does conclude today's program. Thank you for your participation you may disconnect at any time.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Yeah.

Okay.

[music].

Yes.

Okay.

Yes.

[music].

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Okay.

Yes.

Yeah.

Yes.

Okay.

Thank you.

[music].

Okay.

Yes.

[music].

Okay.

[music].

Okay.

Yes.

Okay.

[music].

Okay.

Yes.

Okay.

Great.

Okay.

Yes.

Okay.

Yes.

Okay.

Sure.

Yes.

[music].

Yes.

Okay.

Sure.

Yes.

[music].

Okay.

Yes.

Okay.

Yes.

[music].

Yes.

Okay.

Yes.

Okay.

Yes.

[music].

Yes.

Sure.

[music].

Okay.

Yes.

Okay.

Sure.

Okay.

Yes.

<unk>.

Okay.

Yes.

Thanks.

Yes.

Okay.

Yes.

Sure.

Okay.

[music].

I'll ask a question at that time. Please press star one on your telephone keypad, if you would like to remove your name from the queue. Please press the pound key participants.

Participants will be announced by their name and company.

To give all participants an opportunity to ask their questions. We request a limit of one question per person.

I'd now like to introduce Michael Deveau head of Investor Relations you may begin.

A copy of the release can be found on our IR website at IR Dot dot.

Dot com.

Please note that this call is being recorded live and will be available for replay.

Please take a moment to review our forward looking statements.

During the call we were making forward looking statements about the company's performance, particularly with regard to our outlook for the second quarter and full year 2022.

These statements are based on how we see things today and contain elements of uncertainty.

For additional information concerning the factors that can cause actual results to differ materially from forward looking statements. Please refer to our cautionary statement and risk factors contained in our 10-K filed on February 28, 2022, and in our press release, all of which are on our website.

Today's presentation will include non-GAAP financial measures, which exclude those items that we believe affect comparability.

A reconciliation of these non-GAAP financial measures to their respective GAAP measures is set forth in our press release issued yesterday.

Please note that we would be using comparable results for the first quarter defined as three months of legacy ICF results January through March and three months of legacy <unk> results in both the 2021 and 2022 periods.

These results also exclude the impact of divestitures and acquisitions.

With me on the call today is our CEO Frank Claiborne.

And our executive Vice President and CFO Glen Rector, we will begin with prepared remarks, and then take any questions that you may have.

With that I would now like to introduce Frank.

Thank you Mike.

And Hello, everyone. Thank you for joining us today.

I am pleased to be speaking with you all and excited to share perspectives for my first 90 days as CEO of <unk>.

During today's call I will discuss my initial thoughts since joining.

And highlight our key operating priorities and commitments.

Company for the full year 2022.

As I've spent the last 90 days meeting with ISS colleagues and key customers around the world asking questions and listening in evaluating our business. It has become even more clear to me that ISS has built a very strong foundation with incredible opportunities.

Our business is both a robust diversified portfolio and driven team needed to continue meeting our industry, while delivering sustainable profitable growth.

Simply put I am thrilled to lead and work alone such a passionate team of more than 24000 employees.

With a shared commitment to strengthening customer partnerships and driving differentiated innovations.

Together, we will focus every day on the operational rigor and execution excellence required to deliver even greater value for our customers and shareholders.

Before moving forward at first most acknowledged the human to human humanitarian tragedy basing the Ukrainian people since washes invasion began.

As we have previously stated ISS unequivocally stands with the people of Ukraine.

Our top priority remains the safety of our team members and their families in Ukraine and like many other global companies. We are working closely with local governments to offer assistance where possible.

Aligned with our core values several weeks ago, we limited production and supply of ingredients into Russia to only those that meet the essential needs of people, including food hygiene and medicine.

Our plan at this time is to continue to supply to the best of our ability in accordance with sanctions logistics availability and other key factors.

Now I would like to begin by sharing some initial learnings and insights from my first 90 days with ISS.

I will then turn the call over to Glenn who will provide a detailed look at our first quarter 2022 financial results before providing commentary on our current outlook for the full year 2022. After that we will open the call for Q&A.

Starting on slide six I'd like to reflect on what I've seen and heard from our global colleagues customers.

Bester suppliers and members of our board.

As I noted in my introduction.

Is incredibly well positioned from a portfolio perspective, with an exceptional depth and breadth of product offerings.

<unk> R&D platform that uniquely positions ISS to win with our customers.

Our business is poised to benefit from sustained long term tailwind for profitable growth as we have demonstrated leadership in the most in demand consumer categories. We.

We are the largest player in our industry with unmatched global scale, a strong innovation pipeline and a highly diverse and balanced business mix across categories.

And customers to create significant value.

Collectively these are attractive characteristics and a strong foundation to build upon moving forward.

Equally important however, other clear opportunities to improve our operating practices and ensure that we are achieving on our financial commitments.

This is one of my top priorities going forward as I believe the consistent and consecutive delivery of course within our control is critical to build trust and credibility as Iff's CEO specifically.

Specifically, we are working to cultivate a culture across our entire platform and motivate our teams and ensures accountability across the business.

We are continuing to enhance our operational execution with a renewed focus on instilling greater rigor and excellence aligning our compensation metrics.

Two kpis that are measurable and strongly correlated to value creation.

With all of our initiatives. We are closely focused on consistently delivering on our short and long term financial commitments and creating enhanced value for all stakeholders.

Moving to slide seven I'd like to provide a bit more detail on the process underpinning our efforts to accelerate value creation across ISS.

Our success starts with enhancing our corporate culture to ensure that <unk> efforts worldwide are in line with our vision of strategic excellence.

It starts with establishing a renewed focus on winning.

<unk> outlined the benefits for our team around the world.

To guide our efforts, we are developing a deeper understanding of the sources and drivers of value across the business to help prioritize our investment of energy and resources moving forward.

By understanding the facts, our extended leadership team will have the ability to make better business decisions.

<unk> investment allocations, which we expect will lead to greater financial returns.

With that understanding we will have better visibility into our strategic roadmap essentially setting our profitable growth agenda.

Both the near and long term as we dedicate strategic investments on the highest value opportunities.

Underpinning everything we do will be a commitment to operational rigor and a culture of execution excellence across our platform.

Our results in the first quarter are beginning to reflect this commitment to operating discipline.

<unk> will remain a top priority for our leadership team going forward.

We plan on going into more depth on our strategy and financial outlook moving forward at an investor event that we were planning on having in the second half of 2022 more.

More details to come on that in due course.

Turning now to slide eight I would like to start with the foundational look at our portfolio.

Since my joining and ISS in early February .

<unk> management team have begun a full diagnostic of our strategies and business model to ensure we were operating to the best of our ability.

As part of this process, we are thoroughly examined our business relative to the drivers of our current and future levels of profitability.

To ensure we capture the full cost of doing business, we are going beyond traditional operating costs to account for invested capital such as capex inventory and fixed assets.

This return on invested capital lens, we have incorporated all cost to create a more robust fact base across our entire business portfolio to make better resource decisions.

Based on the preliminary assessment, here's a snapshot of our sub businesses.

As you can see we have a significant amount of high returning businesses, but also like most businesses, we identified opportunities where we can improve our performance.

In high performing areas of the portfolio, we will reinvest with conviction so huge strong profitable growth.

We will also explore all avenues to more efficiently manage resources and our median return business.

Goal of maximizing our performance.

And in areas of our portfolio, where returns are not meeting our expectations or below best in class benchmarks, we intend to either optimize our capital decisions to improve returns.

Valuate appropriate opportunities to de prioritize or exit the business.

As we move forward, we are fully committed to maximizing our portfolio to deliver the most attractive returns and value creation opportunities.

In fact for 2022, we have adjusted our long term incentive plan.

Placing on net debt ratio with return on invested capital performance.

<unk> metrics to increase focus on capital efficiency.

Now before I dive into our first quarter results I want to reemphasize that I am committed to the four key operating priorities, we outlined earlier this year.

Building upon the strong sales momentum we established in 2021, we have first steam to maintain volume growth consistent with overall industry growth rates.

To achieve this we are making significant investments to increase capacity.

<unk> supply chain bottlenecks and driving greater revenue synergy opportunities.

On revenue synergies specifically it is all about expanded revenue growth opportunities and we feel good about the longer term prospects and the power of the portfolio.

To highlight an example, we recently were awarded access and vanilla, a large opportunity with a global customer.

By leveraging heritage and Nbc's global technical Knowhow in ice cream and heritage.

Yes, vanilla sustainability program.

Offered a combination of technical expertise and sustainability that competitors do not have.

The result was not only strong potential revenue in flavors, but also incremental value creation for total assets, including protein multipliers and LPG.

I'm pleased to see in my early days the traction we are making and excited to dig in with the business to unlock more growth opportunities ahead.

Turning to slide 10, I'd like to provide an overview of our solid performance for the first quarter.

Despite the macroeconomic challenges of today's environment, we achieved good sales profit.

And growth across our business.

In the first quarter ISF delivered $3 $2 billion in sales, representing 31% growth or 13% growth on a comparable currency neutral basis.

While inflation and global supply chain, we stick restrictions continue to impact our profitability margin, we achieved 9% growth.

<unk> currency neutral EBITDA.

We also achieved strong adjusted earnings per share excluding amortization of $1 69 for the first quarter.

And as I mentioned, we are evaluating and implementing specific initiatives to ensure we continue to navigate the future headwinds during the remainder of 2022 and beyond.

As a result of increased working capital requirements higher Capex and seasonality our free cash flow results were negatively impacted in the first quarter.

Looking ahead I can assure you this will be a significant focus area for the remainder of the year and we expect strong improvements in the back half of the year.

In terms of deleveraging the balance sheet, we remain on plan as our net debt to credit adjusted EBITDA ratio was four two times.

We also delivered meaningful synergies and productivity gains were more than $30 million in the quarter, including operational efficiencies and deal related synergies.

As mentioned, we continue to prioritize portfolio optimization.

Making strong progress on the divestiture of the microbial control business.

It should be noted that the anticipated closing of our microbial control business is now expected to happen on July versus.

Versus June one.

Previously to provide more time to complete the separation work streams and minimize disruptions and risks to the microbial control business upon close.

With that I'd like to turn the call over to Glenn to provide a closer look into our first quarter financials.

Thank you Frank good morning, and good afternoon to everyone. Let's start on slide 11 with sales performance of each of ipads for businesses.

Together, the Irish health and Biosciences.

And pharma solutions achieved $3 $2 billion in sales revenue in Q1, representing.

Representing comparable currency neutral sales growth of 13%.

No all our sub businesses posted year over year comparable currency neutral growth in the first quarter.

<unk> delivered the most substantial growth with significant broad based strength in our flavors ingredients and food design businesses.

Health <unk> Biosciences, Similarly achieved strong sales growth, having managed headwinds in the health business.

The scent division carry strong momentum from last year to the first quarter with strong results in fine fragrance consumer fragrance and ingredients.

Lastly, pharma solutions also achieved currency neutral sales growth driven by the division's continued strength in its industrial business and resumed demand for pharma.

In terms of sales growth contribution pricing increased approximately 8% and volume grew approximately 5%.

Turning to slide 12, let's walk through our profitability in the quarter.

First quarter, adjusted operating EBITDA totaled $702 million.

Representing 9% comparable currency neutral adjusted operating EBITDA growth versus the first quarter of 2021.

Our adjusted EBITDA margin in the first quarter was 21, 8%.

And on an inflation adjusted basis would have been approximately 175 basis points higher or approximately 23, 5%.

However, this is largely timing related and will change as we progress throughout the year.

Clearly in our results is a charge of approximately $20 million related to expected credit loss on receivables from customers located in Russia and Ukraine.

Took a very proactive approach we quickly instituted broad based pricing actions across our portfolio in response to these pressures.

Consequently, the actions we have taken have resulted in a full dollar cost recovery of total inflation cost.

In the first quarter.

One important call out is that we are seeing the strong cost increases flowing to inventory, which due to our inventory days means that the higher cost will eventually impact the P&L as we progress through the balance of the year.

Now on slide 13, I would like to highlight the underlying dynamics and first quarter performance of each of our business segments.

In the first quarter neurosis strong comparable currency neutral sales growth of 16% was led by double digit growth in food designed and ingredients.

This segment's comparable currency neutral adjusted operating EBITDA growth was also strong at 14%, primarily driven by the divisions pricing actions volume growth and productivity gains.

In health <unk> Biosciences double digit growth in health microbial control and grain processing and high single digit growth in animal nutrition and cultures and food enzymes, so comparable currency neutral sales growth of 10% for the first quarter.

Similar to nourish the segments comparable currency neutral adjusted operating EBITDA growth of 8% was led by pricing volume growth and productivity that help offset mix challenges.

Fine fragrance continued its strong rebound with double digit growth in cosmetic active and fragrance ingredients continued to perform above expectations.

As for consumer fragrance business experienced modest growth in the first quarter.

Overall percent.

On a 6% comparable currency neutral sales growth comparable currency neutral adjusted operating EBITDA declined 2% as inflationary pressures outpaced pricing for the quarter.

As a reminder, there is a delay in pricing recovered about 18 months before we fully recover inflation via price increases.

Finally in pharma solutions, we saw double digit growth in both pharma and industrial to deliver 10% comparable currency neutral sales growth for the quarter.

Volume growth and productivity gains helped drive 10% comparable currency neutral adjusted operating EBITDA.

Now on slide 14, I would like to address our cash flow and leverage positions.

In the first quarter increased working capital requirements.

In the first quarter Capex totaled $132 million, representing approximately four 1% sales.

As a reminder, we anticipate our 'twenty two capex to be approximately 5% of sales due to 'twenty, one capex carryover and increased investments in capacity expansion in key technologies, which will help support growth while also lowering logistics costs.

From a leverage perspective, we are on plan and are continuing to make progress toward achieving our deleveraging target.

Q1 ended net debt to credit adjusted EBITDA ratio was four two times.

Gross debt for the quarter totaled $11 7 billion.

And we finished the first quarter with cash and cash equivalents of $662 million. Despite.

Slide 15 provides our revised business outlook for 2022.

We are adjusting our expected full year 'twenty two revenue up to 12, 6% to 13 billion.

12, three to $12 7 billion it's.

This reflects the effects of additional anticipated pricing accident not incorporated in our original guidance, primarily due to the additional inflationary pressures.

This revision also reflects the expected completion of our microbial controls divestiture on July one one.

One month later than originally planned.

And the acquisition of health right products completed in April .

In addition, our outlook takes into account a weaker euro to dollar currency outlook for the balance of the year.

We continue to expect adjusted operating EBITDA in the range of two five to $2 6 billion as we continue to target full cost recovery of additional inflationary pressures via price increases.

On a comparable currency neutral basis. This translate into sales growth of approximately 9% to 12% versus six 9% previously for the full year and comparable currency neutral adjusted operating EBITDA growth of approximately 4% to 8% which is <unk>.

Unchanged.

It should be noted that while we have increased our sales expectations for the full year due to incremental pricing.

We have reduced our volume expectations, given a more challenging environment.

Including loss revenues as a result of the Russia, Ukraine War.

<unk> global supply chain issues.

And anticipated softer consumer demand as a result of higher energy prices.

In general inflation negatively impacting consumer spending.

One data point is that in early Q2, we have already seen volumes softened.

And for the full year, we are now targeting low single digit volume growth.

And high single digit pricing contributions.

Also based on current market foreign exchange rates, we expect that foreign exchange will negatively impact sales in 2022 by approximately four percentage points.

Two percentage points previously and adjusted.

<unk> operating EBITDA growth by approximately five percentage points versus 4% previously.

These changes now reflect current market exchange rates, particularly the euro where we are.

Assuming that it remains at 106 to the dollar for the balance of the year or a blended full year rate of approximately 108 to the dollar.

We are also confirming our 'twenty two capex spend will be approximately 5% of sales.

In terms of the second quarter, we continue to believe that sales growth will be driven by price increases with volumes contributing much less they did in the first quarter.

From an adjusted EBITDA perspective, we expect to be in the range of 640 to 650 million pressured by unfavorable impact of currency as well as higher inflationary costs flowing from inventories to the income statement.

As I wrap up I want to revisit the four key areas of focus we touched upon in February to update you on our progress at.

Overall, we feel good about our progress across all four areas in Q1 and are confident in our ability to deliver on these commitments this year.

In terms of supporting strong sales momentum, we are increasing our capacity across constraint portions of our portfolio enhancing our supply chain efficiencies.

Most notably in our ATB pharma solutions and ingredients business to ensure that we maintain our volume growth in line with or above the industry.

Relative to executing broad based pricing actions in an effort to react more quickly to the days of evolving environment and better prepare for tomorrow's challenges, we have significantly enhanced our processes implemented new pricing tools and established core pricing teams to oversee each of our.

<unk> units are.

Our focus has been centered around minimizing the amount of time loss between inflation signals and customer pricing actions to ensure that we quickly adjust pricing to.

To protect profitability with these changes we successfully implemented our first round of pricing actions and we cover the total cost of inflation in Q1 2002.

Given additional known inflationary pressures and a lot of uncertainty regarding the future path of inflation. This remains our highest priority.

Accelerating our productivity and expense synergy efforts also remains a key priority and increasingly important in a more challenging macroeconomic environment.

This and we were able to deliver over $30 million of operational efficiency and deal related synergies in the first quarter above our expectations.

As a result, we expect to exceed our original 100 million full year cost reduction target, which is net of reinvestments.

This higher level of productivity is helping office offset lower full year volume expectations.

As we look to accelerate our long term productivity opportunities, we have sharpened our focus on three large areas of productivity.

Procurement efficiencies, notably in indirect spend.

End to end operations efficiencies inclusive of digital enablement yielded mixed enhancements and logistics efficiencies.

And expanding the scale and efficiency of ISS global shared service platform.

Importantly, we will remain prudent in protecting key topline investments, including R&D customer sales and service and technology.

Plan on providing more details of these initiatives at our Q2 earnings call.

Finally, we made further headway in accelerating our noncore divestitures, we are on track to successfully complete the sale of our microbial control business by July one.

We are also targeting additional portfolio optimization and noncore businesses, the best figure opportunities to Delever our balance sheet.

<unk> greater resources toward our higher return businesses.

We are making very good progress in early noncore business in marketing efforts and have already received strong interest from perspective buyers should.

Should these transactions go through we anticipate that they will in aggregate.

<unk> to our go forward growth rate and margin profile with that I'd like to pass the call back to Frank.

Thanks Glenn.

Turning now to slide 16.

As I look back on the last three months I am proud of the work underway to ensure that ISS next chapter is exploit this yet.

Solid results, including consistent volume growth across our portfolio reflects iff's critical role in the consumer goods value chain.

Particularly it made such a challenging operating environment.

Having begun the process of our strategic refresh I look forward to sharing additional updates on ISS long term strategic vision at an investor day in the second half of 2022.

I know many of you have questions as it relates to my perspective on Iff's long term financial targets.

Given we're going through a robust review of our value creation opportunity via our strategy refresh I ask that you give us time to appropriately assess our long term financial objectives.

I want to thank you very much for all of your support.

I know that the best is yet to come for ISS with that I would like to now open the call for questions.

Thank you and at this time, if you would like to ask a question. Please press star one on your Touchtone phone, we do ask that to give opportunity to all participants to ask a question for you request you limit yourself one question per person and we will take our first question from Gunther Zachman with Bernstein. Please go ahead. Your line is open.

Hi, Good morning, Thanks for taking my question I'm going to take money from events in.

The three percentage point increase in organic sales right, Frank that's a 9% to 12% that's almost unprecedented pretty pricey.

Given your tenure at the company and what businesses do you expect to see the biggest price increases.

What businesses to include demand reduction.

Part of your guidance and then I've got a question one b as well, but I will post that.

Sure John So I'll, let Glenn maybe give some specific color on the different business segments, Yes, Hey, Catherine Let me, let me first sort of <unk> by the way good afternoon to you or unpack the $300 million, so sort of the nature of that and I will talk about sort of where it sits so the $300 million change as a function of <unk>.

All items first of all we had some portfolio adjustments to the acquisition of health right and then one additional month of microbial controls.

That's about $130 million of incremental revenue, that's completely offset with our foreign exchange update I E. The stronger euro are the stronger dollar relative to the euro rather basically offset that completely from a revenue standpoint.

The residual is we have incremental pricing of around $370 million and thats all related to raw material increases, which I'll come back to and as we mentioned on the call, we're actually bringing down volume balance of the year.

For a full year of down about $100 million from our original plans. So a little over a half a point full year, we actually were better in the first quarter by a point. So we're taking that in the balance of the year down by $100 million.

Where we're seeing basically the impact of the price slash volume pretty much mirrors, where the cost increases are occurring so we've had more material cost inflation in our nourish business and other businesses. So that that's why you see the the higher growth rates in that business, but we are continuing to see the impact on all the businesses.

So nobody is sort of is exempt from the second round of this $300 million in terms of kind of overall pressure a bit more in Europe than the other business because of the raw material impact.

Great and thanks, Glenn and then <unk> can you provide an update of where you see cost inflation for this.

And as far as we can for next year I know you don't guide for 2023, yet, but if you can share how much earnings do you expect.

Can recover next year some costs that you incurred loss for this year. Please.

Yes. It is.

Is a great question growth or and also something that we're working on now where we don't really have a SaaS in part because there is two.

Parts of the equation one is to understand the overlap of the latest round of raw materials into next year. So there is a carryforward, but then equally are basically the pricing dynamic. So as mentioned we are having to go back in the market because of incremental pricing. So there'll be a full year effect of that as well I would also remind the group that last year.

And we were still in the hole I E. The inflation exceeded pricing in 2021 by $200 million. So we're still plan to basically go after a full capture unfortunately with the latest edition of inflation, it's just going to take a little bit longer into 'twenty, three to sort of get us back to whole.

And we will take our next question from Ken <unk> with Baird. Please go ahead. Your line is open.

Thank you good morning, everybody and Frank welcome to the industry Congrats on the new role.

I guess my question was more so on slide six we have the opportunity section and the third one in terms of reinvesting in capacity.

R&D. So can you just expand on that and if you could just sort of assess the.

Technological capabilities within the company the way you see it at this point I know, it's very early.

In your 10 year life. Thank you.

Yes, Janssen Hi, it's Brian and thanks for the welcome and also for the question a couple of things I want to highlight.

Is and you look at that slide I do want to start with the fact that.

I am very still encouraged by the opportunity that we have in ISS.

Industry trends look very strong overall in the long term around sustainability health and wellness and naturals.

Also ISF with its highly diversified business mix across categories regions and customers I think positions us very well.

Overall plans, but.

R&D portfolio and we will look at the best innovation in R&D opportunities to invest behind as well, but much more to come as we head to the second half of the year.

Okay for the Investor day. Thank you.

And we will take our next question from Jonathan Feeney with consumer edge. Please go ahead. Your line is open.

Good morning, Frank Thanks, Let me.

Add my congratulations you've been very vocal about taking pricing across a broad range of customers.

These are.

It's not quite like gas prices right. These are very sensitive.

Industrial relationships, where companies are intertwined and you.

You mentioned in the script, how it takes time, but I wanted to ask specifically when your customers do pushback on pricing what do they say what are the common pushback together if somebody says no to pricing, what's the reason why that happened.

Eric.

Is that happening or those kinds of things getting said now more often than January as some companies maybe some of your customers are under a little bit more stress now before January .

Yes, John Thanks for the question I'll start on look Glenn.

Add on as well.

One I think the teams have done a really good job starting off this year and working with customers to try to recoup the.

<unk>.

And placed and what we're seeing from an inflationary perspective, so I do feel we're off to a very good start there are pushed back. So I think some of the push backs are in <unk>.

Some of the smaller customers some of our emerging market customers, where price is much more sensitive we are seeing pushback there, but all in all we feel as though we.

We're in a good place and we will continue to work closely with our customers to navigate which as we all know unprecedented times when anything Brad Hey, Thanks, Jonathan for the question I would say first of all obviously, we're not unique as every industry is experiencing substantial increases in inflation in all of our competitors.

They're basically taking prices up as well and as you're well aware as it relates to our value add from our customer supply chain, where attendance, we tend to be a relatively sort of low cost high value add relative to their overall value change and I would say simply put with 60% of.

Our cost structure related to raw materials energy and logistics, it's sort of impossible for us to absorb those levels of increases and rather as our customers will appreciate we're in business to really provide them superior solutions, which require significant investment in innovation customer service capabilities building and maintain.

Winning a very robust global supply chain I would remind everybody, we're adding $200 million of Capex this year alone.

Build out so that's the value we add to our customer and as a result of that we can't sort of if you will speculate on material costs and our customers appreciate that frankly, where we sit relative to our value add they completely appreciate.

What we're doing for them and Thats been reflected in the success of pricing I will note, though there are some sectors as we mentioned in <unk> as an example that theres a lag. So it's not every single customer, whereas our frontier in terms of terms of the pricing, but in general the level of productive dialogue is.

Very very good with our customers.

Thank you.

And we will take our next question from Mark Astrachan with Stifel. Please go ahead.

Yes, thanks, and good morning, everyone.

Maybe to start Glenn what are you assuming for volumes throughout the rest of the year.

Guidance would suggest flattish I guess <unk> you alluded to.

April trends softening were were they positive.

Various two if you've seen competitors pricing.

And the worst is shifted more ISF impact and then <unk>.

I appreciate the commentary on still evaluating the business I guess the question that we get.

Most often is the 26% EBITDA margin target most seem to think that Thats just just unrealistic.

At this point, maybe if you could talk a bit about that that would be helpful. Thank you.

Thanks, Mike So I'll start off with our volume outlook, 5% really actuals for the first quarter, we're actually projecting 1% for the balance of the year. So relatively flattish I would remind everybody. We have a very strong overlap in the last three quarters for the last three quarters of last year.

On average around 10%.

Terms of currency neutral sales of which that was around 8% volume each of the quarters, a very stronger and thats why we actually planned the second half of the year more flattish versus the first.

First half of the year.

While we've taken it down is basically taken the balance of the year down about $100 million in revenue that is basically split into two components. One is the direct impact on Russia, and Ukraine volumes in the second half is really a combination of supply chain and demand issues as the supply chain.

Would include a combination of raw material access as well as China and then generally we just we just feel that we're seeing early signs relative to the consumer pulling back we really don't view this as a not being competitive on a pricing standpoint, but frankly, it's just what we're seeing in the consumer can it's manifested itself later in the last couple of weeks.

A little bit more in the home and personal care side of the business versus sort of the food and beverage or pharma side. So we're not sure honestly, whether thats sort of an end consumer or sort of permanent pullback or adjustment of inventories, but we're just frankly, just being cautious relative to sort of what's going on in the global economy.

And then hey, Mark it's Ryan Thanks for the question and as I can.

You mentioned in some of the early remarks, we are working through our strategy refresh process.

And that does include our long term plan in detail and looking at our current inputs into two.

Through our plan.

We will need some additional time to appropriately assess our long term financial targets.

My immediate focus our management team's focus is on delivering our 'twenty two objectives and the financial goals that we're outlining here. This morning, which of course, there's a lot of focus on pricing as you continue to hear productivity and important levers in working with our customers to grow our absolute sales in dollar.

Profit as we manage through the significant inflationary period.

Longer term.

Mark There is no doubt in my mind, we have a lot of value creation ahead of us in the company.

I believe our business will generate sustainable profitable growth and it will yield margin expansion over time.

As far as your specific question on the 26% adjusted EBITDA target I think it's really safe to say as we look at where we are today.

And if you look at how the World has changed we are not going to be able to achieve that 26% adjusted EBITDA target in 2023.

With that said as I mentioned I do want the time to come back and share with you in the back half of the year, our plans and also our focus on driving really strong profitable growth for the future.

We'll take our next question from Heidi <unk> with BNP Paribas. Please go ahead.

Good morning, just to clarify on pricing again, so you're looking to fully offset the dollar headwind from inflation for the full year. I think you said can you once again explain how you hope to achieve is because its normal industry practice for certain parts of your portfolio makes sense to have a lag so.

Is there another segment offsetting that lag fiscal year. Thank you.

Yes, we actually are lagging Heidi as a reminder, we're 200 million behind from last year.

So there were sort of catching up from last year and capturing.

A large the largest percent of this year, but there is still a lag that will be going into 'twenty three as well.

Okay.

But on a full year 22 basis I think you had said you're looking to fully offsets right. So you won't have that squeeze from raw materials.

Yes, let me let me be clear, we have $200 million from last year from 'twenty. One that we didn't capture we began to implement so if you look at the cumulative 21, which is really the second half of 'twenty, one and all of this year, we're still $200 million bond.

Okay and then the idea is to pass that on as we go into next year. Okay. Thank you.

Thank you and I can say.

We will go next to John Roberts with Credit Suisse. Please go ahead. Your line is open.

So welcome Frank just one question.

<unk> got one of the largest R&D budgets in the industry and the major drug costs are going to best in class R&D management here.

And innovation, our vitality index, we don't get any stage gate processing reported hard to know how productive RMB as for what the right level of spending.

You had a chance to kind of go through the processes within RMB in the center of excellence model and so forth.

There are changes that need to be made there.

Yes, Thanks, John for the question I'll just.

<unk>.

Some of it up in a couple of quick points and based on my experience one I've been very encouraged by.

Some of the recent business update into our R&D centers I, just got back from Palo Alto in California and.

I think what I would highlight is from an R&D perspective, there's three things that come to mind. One is making sure you have the best talent and Thats, a major focus for us and allowing our scientists to innovate number two is we have.

A process a model where you have very close connection with your commercial teams. So your arm in arm. Your scientists in your commercial teams really working on innovations that are going to be meaningful from a customer and consumer perspective, and thats a major focus that we're putting in place and the number three is doing it in an efficient way.

And putting our capital against the biggest R&D opportunities. So early on encouraged this is going to be a focus for us and this also will be a part of our second half Investor day, we will come back and share.

More about some of the exciting projects, we're working on in our pipeline.

Okay.

Then we will take our next question from Matthew Deyoe with Bank of America. Please go ahead. Your line is open.

Good morning, everyone.

Frank one of the criticisms, we often hear about fastest with senior management.

Churn has been pretty elevated following the <unk> acquisition and that perhaps the broader leadership team is relatively experienced.

How do you how do you plan to address this as the new CEO and you think about the team that's around here.

So Matt that's an important question and what I would say is that.

We have to do everything we can as a management team to really build as I've been saying the right culture.

The right focus for the organization.

As I highlighted in my prepared remarks, we have a tremendous opportunity in front of us with Iff's.

But we do need to deliver.

To deliver and we do need to focus on execution excellence.

Yes, there has been some change in the management ranks.

That is something that obviously we.

That's really the focus and I am excited about the passion and the energy I received from so many iaff offers around the world have had a chance to engage with a lot of them.

We're really in a good place as long as we can focus on the hook.

Four priorities that Glenn mentioned earlier.

I do feel good about our opportunity as we work through 'twenty, two and then as we start to build the company for the future.

And we will take our next question from Mike <unk> with Wells Fargo. Please go ahead.

Hey, good morning, welcome Frank.

I guess.

Your background has a lot of integration.

Okay.

And so I'm kind of thinking when you think about the Dupont acquisition.

RMB and putting the company together.

It does seem like the initial outlook for 2003 or the sort of initial goals are going to a little bit off so when.

When you think about.

How we should measure assist there will be inevitably a successful deal together what do you think we need to look forward I know a lot of this will probably come in your analyst day or second half.

Certainly we're looking at Cleveland as a possible site I'm joking, but thanks, Mike.

What should we think about as as the metric or couple of metrics that.

And that at the end of the day Wood Wood wood.

Would suggest this has been a really good deal over time.

Yes.

Yes, Mike I think you recognize as where we started we also are in some unprecedented times from an inflationary perspective in.

Also what's happening.

With regards to China, and Covid lockdowns in what's happening with the reward impossible recessionary pressure. So clearly the world is changing significantly.

I would say.

Is that we will spend time like you said in the second part of this year, but really look at our focus and I keep using this phrase about driving sustainable profitable growth, we want to have a.

Company adds growing top tier within our peer set and from a top line perspective.

Good strong leverage throughout the company.

Our relentless focus on cost and improving our productivity and making sure. We're doing everything that we can deliver for our customers and our shareholders. So I think that will be some of the metrics and we will come back obviously as we get into the second half and give you specific metrics, but thats how I would.

Do you think about it Glenn I don't know if you want to Hey, Mike I would just add one by the way I lived in Cleveland I'm not sure I'm allowed to come back though.

Really at the end of the day, we are trying to deliver a superior outcome for our shareholders and the way to do that as Frank had mentioned is to make sure. We outpace the top line versus the industry. So having superior top line growth and secondarily a superior return on invested capital. The way we are doing that is actually driving significant productivity, which we believe there is.

And allowing that to basically reinvest back helped accelerate the top line and to continue to actually drive some of that to the bottom line, while we're optimizing our portfolio. So to Frank's point that will be sort of a major agenda will be get together later in the year, maybe in Cleveland and Mike just one last one and I did mentioned that ROIC is now part of <unk>.

Our metrics as a team so that's something that we've incorporated.

Okay.

And we will take our next question from Lisa <unk> with Morgan Stanley . Please go ahead.

Hi, good afternoon, and thank you for taking my questions I have two.

So the plus and minuses would be very helpful. And secondly, can you share a little bit what youre seeing in your innovation pipeline.

And what segments are you seeing stronger levels of innovation and also do you see sort of any levels of reformulation activity. Thank you.

Yeah, and just real quickly we're doing a lot of R&D work and health <unk> Biosciences area with regards to our enzymes and focusing on probiotics and also laundry.

Our laundry dish programs with global key accounts, we have work.

Some of our plant based protein and dairy alternatives couple of other quick ones to highlight.

And the scenario some of the renewable biodegradable freight in fragrance ingredients. We're also re.

Focusing.

And nourish around a lot of our flavor technologies and I highlighted one of the big wins that we had with vanilla recently with one of our customers. So we will spend a lot more time here on the pipeline and the portfolio as I mentioned coming up in the second half of the year.

And we will take our next question from David Begleiter with Deutsche Bank. Please go ahead. Your line is open.

Thank you and good morning, and Frank Congratulations as well on the new role.

Frank filling up your overview of the company do you think ISF does a good job capturing the full value.

Products with the customers.

And secondarily, what do you think the IPF does better than competitors.

<unk> versus competitors.

No.

Yes, very good questions I think when you say what do we do better than I'll start there I do think our global scale the diversity of our breadth of our portfolio and how we engage with our customers I think we are.

Leading in many categories and in many areas and Thats something that we will continue to leverage and it also allows for us to work quickly with customers to co create solutions with them. So that to me is a big strength of ours.

What are some of the competitors due to our competitors that are focused in certain areas that I.

Do think have done a nice job from a pricing perspective or have you know in certain categories, a little bit better margin construct and we do and that's really why we're staring into our portfolio to make sure that we put our resources against the best opportunities and where we see those opportunities.

We're going to invest and then where we see opportunities to improve we'll focus there and then in some areas, we will pull back investment or possibly even divest if we need to solar is going to be some things that we're going to be looking at to make sure that we continue to build the strength around our portfolio, but those were some initial thoughts on how I think we are.

Lining up.

With our customers and then how we compare to some of our competitors.

Yes.

And we will take our next question from Lauren Lieberman with Barclays. Please go ahead. Your line is open.

Great. Thanks, good morning.

I was curious I know you touched earlier on.

On pricing and how quickly you move during the first quarter and Glenn in your comments, you more or less referred to that.

Press release that.

That's put out discussing its kind of a new approach to pricing.

From where I sit it feels like that's the first moment.

The company now with it much greater scale.

Taking on the role of industry leader.

Curious, what if anything you've seen in the competitive landscape, how others are now approaching pricing at the industry as a whole is moving faster.

I know, it's been a short period of time, but it's an interesting question in the 10-K ISS roll again as industry leader. Thanks.

Thanks for this newfound scale.

Yes. Thanks for the question, we actually as you recall.

The fourth quarter.

Signaled pretty quickly given we saw this large tsunami of inflation and went out very quickly in the fourth quarter. The first round that press release was really in advance of the second round.

All our competitors are seeing exactly the same.

Inflationary pressures as well so I think that was intended really to help our our teams relative to the customer dialogue sort of understand the dynamics and the impact on the business. Hence the purpose of the press releases as I did mention Eric all of our competitors as Youre well aware are basically in the market.

The same thing in.

Our passing along prices in time as well, we just we just moved fast given we saw in the fourth quarter and as I mentioned on the call. We really also invested in I'll say in infrastructure around the organization to make sure. We are more closely monitoring what's happening in the market and just moving much much much quicker because I think we are concerned that this even the <unk>.

Round, maybe the second of others. So we just want to be prepared to do that and that was.

Was the purpose of that that press release.

Sure.

And we will take our next question from Jeff.

Jeff <unk> with Jpmorgan. Please go ahead your line is open.

Thanks very much.

Originally when you bought.

The Dupont business.

<unk> was to take out $300 million and costs and to spend about $335 million to do it.

And to date.

Think iff's has spent $32 million.

So it seems that the.

Original cost reduction program.

Is moving more slowly.

That is why arent the chargers larger.

And secondly.

On slide eight where you lay out your return on.

As to capital distributions.

It looks like about a third of the company has unsatisfactory returns.

What conclusion to draw from that does that mean that you really need to overhaul.

Structure of the company dramatically or do you draw a different conclusion.

Yes, let me maybe I'll take the second one and come back to the first one is the.

Your conclusion is correct Conservative third argue a third of our business from a capital utilization standpoint needs to improve and there are two major levers so not surprisingly as it relates to some of our non core divestiture work. They would fall within that basket. If you will just continue to optimize the portfolio as one lever the <unk>.

<unk> is really thinking about ultimately a combination of capital investment in those businesses and in addition, how do we think about optimizing the profitability so as part of the.

Roughly $300 million targeted for synergies about half of those were procurement. So it's not surprising that you would have little to no integration related expenses for those those pieces honestly are as we've mentioned in the past we are the farthest behind simply because of this environment is harder to materialize the other half of the ones.

<unk> were sort of midway through in terms of capture to your broader point about how we think about restructuring opportunities. We move beyond a discussion of just synergies deal related synergies was too narrow and we really are focusing more broadly on productivity as I mentioned there are three large buckets operations procurement.

And then share services.

Some one time restructuring charges as we build out our current infrastructure and continue to add capabilities into that network.

And we'll take our next question from Josh Spector with UBS. Please go ahead.

The visibility that you see now or are you pricing ahead of that and does your guide imply a low double digit price exit rate for the year at this point. Thanks.

Yes.

Generally were looking out until the third or fourth quarter for the raw materials energy is more problematic as well as logistics that tends to sort of.

It's really kind of here and now if you will in terms of kind of what's happening in the marketplaces. We've done best estimates based on sort of where the markets are trading relative to energy as well as logistics cost, but generally the raw materials are sort of about six months out but some of them have been a lot of them have been locked in some of them have not so.

So we are continued by the way we're continuing to monitor every single week, we sort of have an update on how we're feeling about the market in general over the last sort of month six weeks. There has been some ebbing and flowing so slightly higher in energy. Some some relief in raw materials, but it hasnt materially different than that 350 ish.

Number that I provided earlier, so relative to sort of a carryover for next year, we still have to sort of work that through as I mentioned, it's a combination of what the tail of this year's annualized raw materials and then very importantly, we got to figure out as well as the tail of the pricing actions into next year as well.

We will take our next question from Christopher Parkinson with Mizuho. Please go ahead. Your line is open.

Alright. Thank you Frank now that you've had just a couple of weeks to evaluate that.

Portfolio initially in kind of the two to three sub businesses that Youre. Most excited about in your remarks, you mentioned probiotics and protein.

Coming from your background.

What's giving you the most excited on a go forward basis. Thank you.

Sure I'll be quick because I know.

We've got a couple more that were waiting on as well, but just to give you. An example enzymes I think are areas that I'm excited about.

And we're going to deploy resources to drive growth and really mix improvement there over time.

There was also I think some really solid areas such as fabric care. We think there is opportunities to improve our cash flow there and then.

We will continue to look at some of the underperforming areas as well and I think this is.

Something in Glen highlight on our four priorities, which is why we have made the decision to.

Exit for instance, our microbial control business and we've announced that divestiture. So those are some examples and like I said, we'll spend much more time.

Opening up and sharing a lot more as we get to the back half of the year.

Sure.

And we'll go next to Andrew <unk> with Barclays Credit. Please go ahead. Your line is open.

Yes, hi, good morning, Glenn.

And then perhaps a question for you.

If you take a step back and look at the balance sheet, we're a little more than a year into the NMB transaction and leverage is essentially where it was at closing.

And I think I heard you said youre dropping the balance sheet metrics from executive compensation. So I guess I just wanted to understand.

Your confidence and the ability to hit that 3.0 times Mark the beginning of 2024, how critical are these divestitures that youre talking about.

And is it right to think that maybe the scope for divestitures can expand particularly as we lap that two year IRS anniversary for <unk>.

Yes, so just a clarification. The reason we dropped the balance sheet metric as we launched a new three year plan. So to some extent this is the window beyond sort of our deleverage so.

I am very very confident that we will hit three less.

Attractive property strategically that alone will basically get us to the goal independent of cash flow to the last point of your question. We're going to continue obviously to take a look at the portfolio. That's part of the strategy refresh.

And there are no further questions at this time I will turn the call back over to Frank Cleveland for any closing remarks.

So thank you.

To all for joining our call I really appreciate.

Your interests in.

The time, we spent this morning discussing our first quarter results.

Hopefully you could hear from myself Glen and on behalf of all of Iff's, We're really encouraged and excited about the future and we look forward to sharing more.

About our plans as we head to the second half of this year and also want to reiterate just how.

Focused we are on a company, making sure we're executing and working with our customers to deliver important solutions for consumers around the world. So thank you and we look forward to speak.

Speaking to you soon.

Thank you and this does conclude today's program. Thank you for your participation you may disconnect at any time.

Q1 2022 International Flavors & Fragrances Inc Earnings Call

Request a DemoDemo

IFF

International Flavors & Fragrances

Earnings